Advertisement

Clinical Rheumatology

, Volume 37, Issue 10, pp 2899–2905 | Cite as

Two cases of sarcoidosis presenting as longitudinally extensive transverse myelitis

  • Amanda Mary Scott
  • Janeth Yinh
  • Timothy McAlindon
  • Robert Kalish
Case Based Review

Abstract

Neurosarcoidosis is uncommon with an incidence of approximately 5 to 15%. Central nervous system involvement can be divided into brain and spinal cord neurosarcoidosis. Spinal cord sarcoidosis is extremely rare, occurring in less than 1% of all sarcoidosis cases. Its manifestations may include cauda equina syndrome, radiculopathy, syringomyelia, cord atrophy, arachnoiditis, and myelopathy or transverse myelitis. We highlight two cases of spinal cord sarcoidosis, each presenting with longitudinally extensive transverse myelitis, that demonstrate the dilemmas that physicians face with regard to diagnosis and treatment. Given its rarity and the diversity of possible manifestations, establishing the diagnosis of spinal cord sarcoidosis is often very difficult. Extensive evaluation must be conducted to rule out primary neurologic, primary rheumatologic, infectious, and neoplastic diseases. MRI often demonstrates hyperintensity on T2-weighted images and enhancement following gadolinium administration. CSF analysis most consistently shows a lymphocytic pleocytosis and elevated proteins. While these less invasive investigations may be helpful, the gold standard for diagnosis is biopsy of neurologic or non-neurologic tissue confirming the presence of non-caseating granulomas. Evidence-based guidelines for the treatment of transverse myelitis secondary to sarcoidosis are lacking due to its rarity; therefore, therapy is based on expert and anecdotal experience and usually consists of high doses of steroids in combination with various immunosuppressive agents. The use of infliximab in particular appears promising, but there is a need for further investigation into the ideal treatment regimen.

Keywords

Immunosuppressive therapy Neurosarcoidosis Sarcoidosis Spinal cord sarcoidosis Transverse myelitis 

Notes

Compliance with ethical standards

Ethical standards

The manuscript does not contain clinical studies or patient data.

Disclosures

None.

References

  1. 1.
    Tana C, Wegener S, Borys E, Pambuccian S, Tchernev G, Tana M, Giamberardino MA, Silingardi M (2015) Challenges in the diagnosis and treatment of neurosarcoidosis. Ann Med 47(7):576–591CrossRefPubMedGoogle Scholar
  2. 2.
    Cação G, Branco A, Meireles M, Alves JE, Mateus A, Silva AM, Santos E (2017) Neurosarcoidosis according to Zajicek and scolding criteria: 15 probable and definite cases, their treatment and outcomes. J Neurol Sci 379:84–88CrossRefPubMedGoogle Scholar
  3. 3.
    Wang L, Li Y (2015) Longitudinal ultra-extensive transverse myelitis as a manifestation of neurosarcoidosis. J Neurol Sci 355(1–2):64–67CrossRefPubMedGoogle Scholar
  4. 4.
    Durel CA, Marignier R, Maucort-Boulch D, Iwaz J, Berthoux E, Ruivard M, André M, le Guenno G, Pérard L, Dufour JF, Turcu A, Antoine JC, Camdessanche JP, Delboy T, Sève P (2016) Clinical features and prognostic factors of spinal cord sarcoidosis: a multicenter observational study of 20 biopsy-proven patients. J Neurol 263(5):981–990CrossRefPubMedGoogle Scholar
  5. 5.
    Ungprasert P, Matteson EL (2017) Neurosarcoidosis. Rheum Dis Clin N Am 43(4):593–606CrossRefGoogle Scholar
  6. 6.
    Cohen-Aubart F, Galanaud D, Grabli D, Haroche J, Amoura Z, Chapelon-Abric C, Lyon-Caen O, Valeyre D, Piette JC (2010) Spinal cord sarcoidosis: clinical and laboratory profile and outcome of 31 patients in a case-control study. Medicine (Baltimore) 89(2):133–140CrossRefGoogle Scholar
  7. 7.
    Fried ED, Landau AJ, Sher JH, Rao C (1993) Spinal cord sarcoidosis: a case report and review of the literature. J Assoc Acad Minor Phys 4(4):132–137PubMedGoogle Scholar
  8. 8.
    Zajicek JP, Scolding NJ, Foster O, Rovaris M, Evanson J, Moseley IF, Scadding JW, Thompson EJ, Chamoun V, Miller DH, McDonald W, Mitchell D (1999) Central nervous system sarcoidosis—diagnosis and management. QJM 92(2):103–117CrossRefPubMedGoogle Scholar
  9. 9.
    Cerar T, Strle F, Stupica D, Ruzic-Sabljic E, McHugh G, Steere AC, Strle K (2016) Differences in genotype, clinical features, and inflammatory potential of Borrelia burgdorferi sensu stricto strains from Europe and the United States. Emerg Infect Dis 22(5):818–827CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Halperin JJ (2018) Diagnosis and management of Lyme neuroborreliosis. Expert Rev Anti-Infect Ther 16(1):5–11CrossRefPubMedGoogle Scholar
  11. 11.
    Halperin JJ (2011) Neurologic manifestations of Lyme disease. Curr Infect Dis Rep 13(4):360–366CrossRefPubMedGoogle Scholar

Copyright information

© International League of Associations for Rheumatology (ILAR) 2018

Authors and Affiliations

  • Amanda Mary Scott
    • 1
  • Janeth Yinh
    • 1
  • Timothy McAlindon
    • 1
  • Robert Kalish
    • 1
  1. 1.Rheumatology DivisionTufts Medical CenterBostonUSA

Personalised recommendations